Concomitant immune-related events in XXXX : implications for monitoring chelator therapy.

@entity1 @entity219 @entity2361 @entity31000 @entity2360 @entity792
BACKGROUND AND AIMS: Current guidelines favor the use of chelating agents ( @entity2361 , @entity31000 ) in first line therapy of symptomatic @entity2360 @entity1 . Development of chelator induced immunological adverse events are a concern especially under @entity2361 therapy. This study assessed the prevalence of co-existing or therapy-related immune-mediated diseases in @entity2360 @entity1 , and evaluated the role of antinuclear antibodies in therapy monitoring. METHODS: We retrospectively analyzed 235 @entity2360 @entity1 . Medical regimens were classified and analyzed in relation to adverse events and antinuclear antibody courses. RESULTS: Coexisting immune-mediated diseases were evident in 19/235 (8.1  %) @entity1 , of which 13/235 (5.5  %) had pre-existing @entity792 . Six @entity1 (2.6  %) developed an @entity792 under therapy, all of them under long-term @entity2361 treatment. Data relating to antinuclear antibody courses during treatment and adverse events were available for @entity1 treated with @entity2361 (n   =   91), @entity31000 (n   =   58), and @entity219 salts (n   =   58). No significant increase in antinuclear antibody titers in @entity1 treated with @entity2361 (16/91; 17.6  %), @entity31000 (12/58; 20.7  %), and @entity219 (7/58; 12.1  %) were found. CONCLUSION: Under long-term @entity2361 therapy a minority of @entity1 developed immune-mediated disease. Elevations in antinuclear antibodies were found frequently, but no correlations were evident between increases in antinuclear antibodies and the development of immune-mediated diseases or medical regimes. Thus, the value of antinuclear antibodies for monitoring adverse events under chelator therapy seems to be limited.
